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Background: Dementia is a common and complex condition. Evidence-based guidelines for the management of
people with dementia in general practice exist; however, detection, diagnosis and disclosure of dementia have
been identified as potential evidence-practice gaps. Interventions to implement guidelines into practice have had
varying success. The use of theory in designing implementation interventions has been limited, but is advocated
because of its potential to yield more effective interventions and aid understanding of factors modifying the
magnitude of intervention effects across trials. This protocol describes methods of a randomised trial that tests a
theory-informed implementation intervention that, if effective, may provide benefits for patients with dementia and
their carers.
Aims: This trial aims to estimate the effectiveness of a theory-informed intervention to increase GPs’ (in Victoria,
Australia) adherence to a clinical guideline for the detection, diagnosis, and management of dementia in general
practice, compared with providing GPs with a printed copy of the guideline. Primary objectives include testing if
the intervention is effective in increasing the percentage of patients with suspected cognitive impairment who
receive care consistent with two key guideline recommendations: receipt of a i) formal cognitive assessment, and
ii) depression assessment using a validated scale (primary outcomes for the trial).
Methods: The design is a parallel cluster randomised trial, with clusters being general practices. We aim to recruit
60 practices per group. Practices will be randomised to the intervention and control groups using restricted
randomisation. Patients meeting the inclusion criteria, and GPs’ detection and diagnosis behaviours directed toward
these patients, will be identified and measured via an electronic search of the medical records nine months after
the start of the intervention. Practitioners in the control group will receive a printed copy of the guideline. In
addition to receipt of the printed guideline, practitioners in the intervention group will be invited to participate in
an interactive, opinion leader-led, educational face-to-face workshop. The theory-informed intervention aims to
address identified barriers to and enablers of implementation of recommendations. Researchers responsible for
identifying the cohort of patients with suspected cognitive impairment, and their detection and diagnosis
outcomes, will be blind to group allocation.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12611001032943 (date registered 28
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Dementia is a global problem largely driven by popula-
tion ageing. A recent review of the worldwide prevalence
of dementia in those aged 60 years and over found that
the age standardised rates varied from 4.19% to 8.5%. In
2010, the number of people with dementia was 35.56
million, and this number is expected to increase to
115.38 million by 2050 [1]. In 2011, there were an esti-
mated 298,000 Australians with dementia, 74% of whom
were aged 75 years and older. The number of Australians
with dementia is projected to reach 900,000 by 2050 [2].
Evidence-based clinical practice guidelines (CPGs)
for the management of people with dementia have
been published by a number of agencies, including the
Scottish Intercollegiate Guidelines Network (SIGN)
[3]. These guidelines include a series of evidence-based
recommendations for the detection, diagnosis and
management of people with dementia, both in the
community and in residential care, and focus on inves-
tigations and interventions which have been shown
from research to directly benefit people with dementia.
We undertook a systematic search (January 2012) for
clinical practice guidelines published subsequent to theTable 1 Recommendations of the IRIS trial
Recommendation Det
Detection and diagnosis
Conduct a cognitive assessment using the Mini Mental State
Examination (MMSE) in individuals with suspected cognitive
impairment.
SIGN
Assess for co-morbid depression using a validated tool. SIGN
valid
Dep
Refer to Cognitive, Dementia and Memory Service (CDAMS) or
specialist for access to dementia-modifying medications.
Loca
Guid
inte
(e.g.
med
Refer for head/brain computed tomography (CT) scan. SIGN
stru
Aus
Review current medication (prescription and over the counter) that
may cause cognitive impairment.
Not
the
Refer for pathology testing. SIGN
con
Management
Disclose or reinforce a diagnosis of dementia. Not
reco
with
invo
with
reco
dem
othe
*Grade of recommendation relates to the strength of evidence underlying the reco
highest level of evidence. Details of the types of evidence underlying each grade a
†Recommendation arrived at through discussion and consensus among the IRIS clin
‡Recommended best practice based on the clinical experience of the SIGN guidelinSIGN guideline and identified 14, the majority of
which share the same recommendations. The IRIS
(Implementing Research Implementation Strategies)
trial focuses primarily on detection and diagnosis rec-
ommendations from the SIGN guideline, with some
adaptation for the Australian context, and two recom-
mendations considered best practice by the IRIS clin-
ical investigators (Table 1).
Detection, diagnosis and disclosure of dementia have
been identified as potential evidence-practice gaps in
Australian general medical practice [4,5]. Delayed diag-
nosis of dementia and delay in the recognition of de-
mentia by GPs can impact outcome and restrict access
to support for people with dementia and their carers.
Early diagnosis can facilitate timely referral to education,
counselling and support services for people with demen-
tia and their carers, and early diagnosis is more likely to
allow input from the patients about their care plans [6].
For example, there is evidence that caregiver interventions
to improve well-being can delay entry to residential aged
care in people with dementia [7]. Early differential diagno-
sis is also important in maximising the benefits of treat-
ments and assists the patient and carer in understandingails and source
guideline (grade B recommendation*) [3].
guideline (grade B recommendation*) [3]. We include the following as
ated scales: Geriatric Depression Scale (GDS), Hamilton Rating Scale for
ression, and Even Briefer Assessment Scale for Depression.
l adaptation of SIGN guideline (grade B recommendation*) [3].
eline makes recommendations about specific pharmacological
rventions
, use of cholinesterase inhibitors). Access to dementia-modifying
ication is via specialist referral in Australia.
guideline (grade C recommendation*) [3]. Guideline recommends
ctural imaging. We focus only on referral for CT scan since GPs in
tralia cannot refer for a MediCare rebatable magnetic resonance imaging.
a recommendation of the SIGN guideline. Considered best practice by
IRIS clinical investigators†.
guideline (good practice point‡) [3]. Supported by other guidelines and
sidered best practice by the IRIS clinical investigators†.
a recommendation of the SIGN guideline [3]. The SIGN guideline
mmends that healthcare professionals should be aware that many people
dementia can understand their diagnosis, receive information and be
lved in decision-making (grade C recommendation); that some people
dementia may not wish to know their diagnosis (grade C
mmendation); and that in some situations, disclosure of a diagnosis of
entia may be inappropriate (grade D recommendation). Supported by
r guidelines and considered best practice by the IRIS clinical investigators†.
mmendation. Recommendations range from A to D, with A providing the
re available in the SIGN guideline [3] (pg. 2).
ical investigators.
e development group [3].
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of cognitive impairment by a GP to confirmed diagnosis
or exclusion of dementia is considered too long and
may take years [9]. International studies have estimated
the average time from first symptoms to diagnosis, as
reported by informants, to be between one and three
years [10,11], with symptoms recorded in GPs’ medical
records as early as five years before diagnosis [12]. A
systematic review of qualitative studies suggests that
diagnostic uncertainty or insufficient knowledge or ex-
perience, difficulties in disclosing the diagnosis, and the
stigma attached to dementia, are barriers to diagnosis
of dementia reported by primary care practitioners [13].
A limited number of randomised trials have tested the
effectiveness of interventions to increase GPs’ awareness
and diagnosis of people with suspected cognitive impair-
ment and management of dementia [14-19]. These trials
have evaluated a range of interventions (e.g., educational
interventions, decision support software, practice-based
workshops, blended learning), across different settings
(United Kingdom, United States, Germany and France).
The intervention effects from these trials have been
mixed.
More generally, interventions designed to implement
guidelines into practice have had varying success [20]. It
has been suggested that this may be due, in part, to a
lack of explicit rationale for the intervention choice, or
the use of inappropriate methods to design the interven-
tions [21-23]. Using theory to inform the design of inter-
ventions to implement guidelines into practice may
provide a more effective approach [24]. In addition, the-
ory provides a framework that can aid identification of
factors that may modify the magnitude of intervention
effects across trials [25,26]. The Theoretical Domains
Framework of behaviour change provides a comprehen-
sive framework for designing such interventions, offering
broad coverage of potential change pathways [27].
A number of randomised trials are currently underway
aiming to improve the management of dementia [28-31].
However, to our knowledge, no study in the Australian
setting has investigated a theory-informed intervention
to improve clinical practice in primary care in relation
to detection and diagnosis of dementia.Aim and objectives
The aim of the IRIS trial is to determine if a theory-
informed behaviour change intervention is effective in
increasing GPs’ adherence to a clinical practice guideline
for the detection, diagnosis and management of demen-
tia in general practice (in Victoria, Australia). Our pri-
mary objectives are to establish if the intervention is
effective in increasing the percentage of patients with
suspected cognitive impairment who receive:1. Cognitive assessment using the Mini Mental State
Examination (MMSE); and,
2. Depression assessment using a validated scale.
These objectives reflect two key recommendations of
the SIGN guideline for improving the detection and
diagnosis of dementia (with level B evidence), for which
there are identified evidence-practice gaps.
Secondary objectives include estimating the effects of
the intervention for secondary outcomes in the categor-
ies of: GP diagnosis behaviours; proxy measures of GP
diagnosis and management behaviours; and hypothesised
mediators of GP behaviour (measures of motivation,
capability, and opportunity to behave in a manner con-
sistent with recommended behaviours [32]). In addition,
we will conduct cost-effectiveness analyses to quantify
the tradeoff between the hypothesised improvement in
clinical practice and the additional costs (savings) arising
from delivery of the intervention and from any subse-
quent changes in clinical practice and healthcare
utilization within the trial period.
Methods
The methods of the IRIS trial draw upon those of our
previous implementation trials conducted in primary
care settings [33,34]. At the time of submission of the
trial protocol, the trial intervention has been delivered,
and the baseline questionnaire measuring predictors of
GPs’ diagnostic and management behaviours have been
collected. Collection of patient level data has just begun
(April 16).
Trial design
The design of this trial is a parallel cluster randomised
trial (C-RT) with clusters being general practices, includ-
ing one or more GPs and their patients. A cluster
randomised design was chosen since the intervention
was targeted at GPs. Clustering at the level of the prac-
tice allows evaluation of the intervention as it would be
delivered in a real world context, evaluating the direct
effect of the intervention in combination with any ‘con-
tamination’ effect arising from diffusion of the interven-
tion amongst GPs within the same practice [35].
Eligibility and recruitment
Recruitment of general practices
All GPs within the state of Victoria, Australia, listed on
the Australasian Medical Publishing Company (AMPCo)
database as of September 30, 2011, will be approached
to participate in the trial. The AMPCo database is cre-
ated from an amalgamation of sources and provides a
comprehensive list of GPs in Australia. Practitioners will
receive a letter of invitation, including an explanatory
statement and consent form. Those who do not respond
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tween September 2011 and February 2012. When a first
GP in a practice agrees to participate, he or she will be
sent invitation letters to distribute to GP colleagues who
work in the same practice to facilitate more GPs to enrol
per practice.
To increase awareness of the trial, notices will be
placed in the newsletters of the Divisions of General
Practice and Royal Australasian College of General Prac-
titioners. Strategies to promote participation include of-
fering continuing medical education points and an
opportunity to enhance the detection and diagnosis of
people with suspected cognitive impairment and their
ongoing management. Practitioners will be provided
with an honorarium (AUD 300) as a contribution toward
practice staff time in running the electronic search of
the medical records.
Identification of patients
Patients will be identified through an electronic search
of the GPs’ medical records. We will receive de-
identified data extracted from the medical records, and
patients will not be contacted for any information. For
these reasons, and because of the nature of the interven-
tion (see ‘Interventions’ section), patients will not be
consented to participate in the trial. This is consistent
with Recommendation 3 of ‘The Ottawa Statement on
the Ethical Design and Conduct of Cluster Randomized
Trials’ [36], in that patients in this trial do not meet the
criteria to be considered research participants.
A search module has been specifically developed as
part of Pen Computer Systems (Pty Ltd) Clinical Audit
Tool™ (CAT). The CAT was developed to analyse clinical
information captured within general practice clinical
desktop systems (e.g., Medical Director). Many Divisions
of General Practice (renamed Medicare Locals in June
2012) within Victoria subscribe to the CAT, providing
free access for practices within their jurisdiction. The de-
veloped module will only be activated in participating
general practices, and when run, will yield a data file in-
cluding all patients aged 70 years and older. The file will
include demographic data (age and sex), coded diagno-
ses of cognitive impairment and dementia, extracted
free text and dates related to cognitive and depression
assessment and referral for CT scan and specialist
services. To maintain anonymity of the patients, the
extracted free text will be a maximum of 40 characters
in length surrounding identified search terms. Search
terms were compiled with input from the IRIS clinical
investigators.
The search module will be run nine months after the
start of the intervention (delivery of a workshop), and
will search the medical records over the previous three
years. From the extracted data, two cohorts of patientswill be identified. The first cohort (cohort 1) will include
all patients aged 70 years and older at baseline (June 22,
2012), but without a diagnosis of dementia. The second,
and primary cohort of interest (cohort 2), will include
the subset of cohort 1 patients for whom the GP has
noted a suspicion of cognitive impairment in the medical
records in the period prior to intervention delivery
(prior to June 22, 2012). These patients will be identified
through coded fields (e.g., coded diagnosis of cognitive
impairment) and review of free text entries. Two re-
searchers (with healthcare qualifications), who are blind
to the intervention group, will independently review the
free text entries. Disagreements will be resolved via dis-
cussion with a geriatrician who will not be informed of
the group allocation of the patient.
The different cohorts will be used to examine GPs’
clinical behaviour with all older people (cohort 1) and
with those patients whom the GP previously suspected
of having cognitive impairment (cohort 2). Inclusion of
the former cohort allows examination of whether the
intervention is effective in raising GPs’ awareness and
diagnosis of cognitive impairment and dementia in all
older patients (including those with and without previ-
ously noted cognitive impairment).
Inclusion criteria
General practices will be included if the following
criteria are met:
1. The practice is located in the state of Victoria,
Australia.
2. At least one GP within the practice provides written
informed consent.
3. The practice utilises a CAT-compatible general
practice clinical desktop system (either Medical
Director or Best Practice).
General practitioners will be included if the following
criteria are met:
1. The GP works in a participating practice.
2. The GP provides written informed consent.
Patients will be included in cohort 1 if the following
criteria are met:
1. The patient is ‘active’ (where ‘active’ is defined as a
minimum of three visits recorded in the general
practice clinical desktop system in the two-year
period preceding follow-up [nine months after the
start of the intervention]).
2. The patient is aged 70 years or older at baseline.
3. The patient visits the GP in the follow-up period
(nine months after the start of the intervention).
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suspected cognitive impairment) if any of the following
additional criteria are met in the two-year period prior
to the start of the intervention:
1. The patient has a coded diagnosis of cognitive
impairment or free text indicating a suspicion of
cognitive impairment (e.g., ‘confusion,’ ‘muddled’).
2. The patient has had an MMSE in isolation of a
routine health assessment for people aged 75 years
and older (75+ Health Check [37]) (an indication of
the GP’s suspicion of cognitive impairment).
3. The patient has had an MMSE as part of a routine
health assessment for people aged 75 years and older
(75+ Health Check [37]) with a score that indicates
cognitive impairment (i.e., a score between 10 and 24).
Exclusion criteria
General practices will be excluded if the practice princi-
pal or practice manager refuses participation.
General practitioners will be excluded if they work at
more than one of the general practices included in the
trial.
Patients will be excluded from both cohorts 1 and 2 if,
within the two-year period prior to the start of the inter-
vention, the patient record has a coded diagnosis of de-
mentia or contains free text indicating dementia (e.g.,
Alzheimer’s, senility, dementia). Patients with dementia
will be excluded since only GPs’ detection and diagnosis
(not management) behaviours of dementia can be mea-
sured through patient medical records.
Randomisation and allocation concealment
General practices meeting the inclusion criteria will be
randomly allocated to the intervention or control
groups. Restricted randomisation will be used to reduce
the probability of baseline imbalance in factors thought
to be predictive of the outcomes, and for potential gain
in statistical power [38]. Four strata will be defined by
geographical location of the practice (rural or metropol-
itan area) and the number of GPs per practice (<6 GPs
and ≥6 GPs per practice). Geographical location may ex-
plain variation in some of the health service utilisation
outcomes (e.g., imaging and specialist services), because of
geographic proximity to services and geographic variation
in socioeconomic status [39]. Cluster size (in our trial
measured by the number of GPs per practice) is com-
monly employed as a stratification variable in cluster trials
since it is often considered a proxy for characteristics of
the cluster that may be predictive of the outcomes (e.g.,
educational environment within the practice) [35,38].
Within stratum, practices will be randomised with
equal probability (1:1 ratio) to the intervention and con-
trol groups using computer-generated random numbers.Practices will be randomised at the same time by a stat-
istician independent of the trial team. The statistician
will be provided with a file containing only practice
identification codes and stratification variables. Thus,
the statistician will be provided with no identifying
information.
Blinding
The investigators will not be blind to group allocation
since they will be involved in the delivery of the inter-
vention. An exception to this is the trial statistician
(JEM), who will be blinded to group allocation. Due to
the nature of the intervention, GPs will not be blind to
group allocation. General practitioners will be informed
through recruitment information that they will be ran-
domly allocated to receive access to materials about the
detection, diagnosis and management of dementia, or a
face-to-face workshop and access to materials. Self-
report questionnaires completed by GPs will be entered
by trial personnel who are blind to group allocation. De-
tection and diagnosis outcomes will be collected via the
execution of a computer script (by general practice
personnel) that extracts de-identified data from the prac-
tices’ electronic medical records.
Interventions
Control group
The control group will receive a printed copy of the
SIGN guideline for the management of patients with de-
mentia [3].
Intervention group
In addition to receipt of the printed guideline, the GPs
randomised to the intervention arm will receive an inter-
vention designed to address the barriers to and enablers
of implementation of the evidence-based recommenda-
tions. In phase one of this project, interviews were
conducted with GPs in Victoria, Australia, underpinned
by the Theoretical Domains Framework [40], a frame-
work grounded in behavioural theory. The interviews
were analysed using content and thematic analysis to
identify the barriers and enablers relevant to each of the
clinical behaviours. For example, the main factors identi-
fied as barriers to assessing cognitive function using a
validated scale included negative beliefs about formal
cognitive testing and the scales themselves (Beliefs about
consequences); discomfort in administering the tests
(Emotion); (possibly due to) limited training and confi-
dence in using them (Skills, Beliefs about capabilities);
limited access to tests or time and resources to under-
take formal cognitive testing (Environmental context
and resources); and patients finding testing uncomfort-
able or patients/family refusing testing (Social influ-
ences). The main factors enabling formal cognitive
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undertake the assessment (Knowledge); possessing the
necessary skills and confidence to do so (Skills; Beliefs
about capabilities); and adequate time and resources
(Environmental context and resources).
The intervention is an interactive, educational face-to-
face workshop, led by an Australian geriatrician with
expertise in dementia. The content of the workshop was
designed using an intervention mapping process where
the research team chose behaviour change techniques to
address barriers/enablers within theoretical domains
[24,41]. The behaviour change techniques delivered dur-
ing the workshop will include: Information provision;
Persuasive communication; Information regarding be-
haviour, outcome; Feedback; Social processes of encour-
agement, pressure, support; Self-monitoring; Modelling/
demonstration of behaviour by others; Increasing skills;
Coping skills; Rehearsal of relevant skills; and Action
planning. The workshop will be a combination of didac-
tic presentations given by opinion leaders, and small
group discussions led by trained facilitators.
Intervention fidelity
We plan to evaluate the fidelity of delivery of the inter-
vention to assess the extent to which the intervention is
delivered as planned [42]. The intervention workshops
will be audio and video recorded, and these recordings
will be analysed to determine which elements of the
planned intervention were actually delivered.Figure 1 Timing of recruitment, intervention delivery, follow-up of prTiming of recruitment, intervention delivery, and follow-up
The intervention educational workshop took place on
the June 23, 2012. The guidelines were sent to the
control group GPs in November 2012. Questionnaires
measuring predictors of GPs’ detection, diagnosis, and
management behaviours were collected at baseline and
will be collected nine months post the educational
workshop (April 2013). The cohort of patients meeting
the inclusion criteria for the trial, and GPs’ detection
and diagnosis behaviours of these patients, will be iden-
tified and measured via the CAT nine months post the
educational workshop (from April 2013). Figure 1 de-
picts the timing of recruitment, intervention delivery,
and follow-up.
Study outcomes
Primary outcomes
The primary outcomes (cognitive assessment using
MMSE, depression assessment using validated scale)
provide measures of whether the GPs undertake a for-
mal assessment for cognitive impairment and depression
(Table 2). These behaviours have been selected since
they reflect the two key recommendations from the
SIGN guideline [3] (with level B evidence) that have
identified evidence-practice gaps and have the potential
to be implemented into practice through behaviour
change (i.e., there are no structural barriers to the imple-
mentation of the practice). In addition, these behaviours
can be objectively measured through the CAT.actitioner participants and patients.
Table 2 Outcome measures
Outcome Data collection method Outcome assessment period Source Level data collected
Primary outcomes
GP behaviour
Cognitive assessment using MMSE1* Clinical Audit Tool (CAT) electronic
search
Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Depression assessment using validated scale1* CAT electronic search Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Secondary outcomes
GP behaviour
Referral to CDAMS or specialist1† CAT electronic search Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Referral for CT scan1* CAT electronic search Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Dementia Diagnosis1 CAT electronic search Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Cognitive assessment using MMSE (all patients aged 70+ years)3* CAT electronic search Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Reported suspicion of cognitive impairment (all patients aged 70+
years)3
CAT electronic search Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Dementia diagnosis (all patients aged 70+ years)3 CAT electronic search Baseline & 9 months post workshop
delivery2
Medical
record
Patient
Proxy measures of GP behaviour
Self-report of adherence to recommended behaviours: Questionnaire Baseline & 9 months post workshop
delivery
Practitioner Practitioner
Cognitive assessment using MMSE* (1 item each)
Depression assessment using validated scale*
Referral to CDAMS or specialist†
Referral for CT scan*
Review of medications§
Ordering of pathology tests‡§
Behavioural simulation to adhere to recommended behaviours: Questionnaire
(clinical vignettes)
9 months post workshop delivery Practitioner Practitioner
Cognitive assessment using MMSE*
Depression assessment using validated scale*
Referral to CDAMS or specialist†
Referral for CT scan*
Review of medications§
Ordering of pathology tests‡§
M
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Table 2 Outcome measures (Continued)
Disclosure of diagnosis to patient‡§
Disclosure of diagnosis to carer‡§
Hypothesised mediators of GP behaviour
Intention to adhere to recommended behaviours: Questionnaire Baseline & 9 months post workshop
delivery
Practitioner Practitioner
Cognitive assessment using MMSE* (3 items)
Depression assessment using validated scale* (3 items)
Disclosure of diagnosis to patient‡§ (6 items)
Disclosure of diagnosis to carer‡§ (2 items)
Behavioural constructs for primary outcomes4 Questionnaire Baseline & 9 months post workshop
delivery
Practitioner Practitioner
(47 items)
Symbols indicate source of recommended behaviour: * SIGN guideline; † Local adaptation of SIGN guideline (by IRIS clinical investigators); ‡ Other guidelines; § Considered best practice by the IRIS
clinical investigators.
1Active patients aged 70 years and over in whom the GP suspects cognitive impairment at baseline (cohort 2). Active is defined as a minimum of three visits recorded in the general practice clinical desktop system in
the two-year period preceding follow-up (nine months post workshop delivery)).
2For this variable, the outcome is measured over the two-year period prior to randomisation and nine months post workshop delivery.
3Active patients aged 70 years and older (cohort 1). See footnote 1 for the definition of active.
4Table 3 provides details of behavioural construct domains for the primary outcomes.
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GP behaviour The secondary outcomes include mea-
sures of GPs’ diagnostic behaviours (Table 2). The
chosen behaviours are recommendations from the SIGN
guideline [3], including some adaptation for the Australian
context (e.g., referral to CDAMS, details of adaptation
available in Table 1). Two behaviours, ‘review of medi-
cations’ and ‘ordering of pathology tests’ are not recom-
mendations of the SIGN guideline, but were considered
best practice by the IRIS clinical investigators (Table 1).
We have also included outcomes (dementia diagnosis,
reported suspicion of cognitive impairment) measuring
whether the intervention is effective in raising GPs’ aware-
ness and diagnosis of cognitive impairment and dementia
for all patients aged 70 years and older (cohort 1).
Proxy measures of GP behaviour Proxy measures of
all GP diagnostic behaviours have been included. For
some diagnostic behaviours (referral to specialist, review
of medications, ordering of pathology tests), it is not
possible to use the CAT. Proxy measures provide an al-
ternative method for measuring behaviour in such cir-
cumstances, and there is some evidence showing they
are predictive of behaviour [43]. We have included proxyTable 3 Behavioural construct domains (hypothesised mediat
Domains Domain definitions [27] (adapted from Mic
Motivation
Intention3 A conscious decision to perform a behaviour o
Beliefs about capabilities Acceptance of the truth, reality or validity abou
can put to constructive use
Beliefs about
consequences
Acceptance of the truth, reality or validity abou
situation
Emotion A complex reaction pattern, involving experient
by which the individual attempts to deal with a
Capability
Knowledge An awareness of the existence of something
Skills An ability or proficiency acquired through prac
Memory, attention and
decision processes
The ability to retain information, focus selectiv
choose between two or more alternatives
Opportunity
Environmental context
and resources
Any circumstance of a person’s situation or en
the development of skills and abilities, indepen
behaviour
Social influences Those interpersonal processes that can cause i
feelings or behaviours
1Cognitive assessment using MMSE. Three items per behavioural construct domain,
of 25 items.
2Depression assessment using validated scale. Three items per behavioural construc
providing a total of 25 items.
3Intention referred to as ‘Motivation and goals’ in the Theoretical Domains Framewmeasures for the two management behaviours, disclos-
ure of diagnosis of dementia to (i) patients and (ii)
carers. While disclosure of diagnosis is not a recommen-
dation of the SIGN guideline, there are many ethical ar-
guments favouring disclosure [44], and the IRIS clinical
investigators strongly advocated for disclosure. Further-
more, disclosure was identified as salient in the inter-
views with GPs in phase I of this project.
Mediators of GP behaviour For the two key recom-
mendations (undertaking a formal assessment for cogni-
tive impairment and for depression), potential mediators
of GP behaviour include measures of behavioural con-
structs (e.g., emotion, knowledge, skills, and social influ-
ences) (Table 3). These mediators reflect the barriers
and enablers that were identified in phase I of this pro-
ject (through interviews with GPs), and were targeted
through the intervention components. We include mea-
sures of intention to adhere to the two key recommen-
dations, since intention in many theories is considered
the most immediate predictor of behaviour [45], and we
hypothesise that intention will mediate the relationship
between GPs’ motivation and behaviour. If the interven-
tion is effective, we posit that differences in theseors of GP behaviour)
hie et al. [40]) Domain measured for
behaviour
Cognitive
assessment1
Depression
assessment2
r a resolve to act in a certain way ✓ ✓
t an ability, talent or facility that a person ✓ ✓
t outcomes of a behaviour in a given ✓ ✓
ial, behavioural and physiological elements,
personally significant matter or event
✓ ✓
✓ ✓
tice ✓ ✓
ely on aspects of the environment, and ✗ ✓
vironment that discourages or encourages
dence, social competence, and adaptive
✓ ✓
ndividuals to change their thoughts, ✓ ✗
except for Beliefs about consequences, which is four items; providing a total
t domain, except for Beliefs about consequences, which is four items;
ork [40].
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plays the causal pathway demonstrating the hypothesised
relationship between the intervention, mediators and be-
haviour. Examination of the effects of the intervention
along the causal pathway has been restricted to the pri-
mary outcomes to limit respondent burden.
We have included measures of intention for the two
management behaviours, disclosure of diagnosis of de-
mentia to (i) patients and (ii) carers.
Outcome measurement
Table 4 provides a summary of the measurement tools. In
brief, GPs’ detection and diagnostic behaviours will be mea-
sured through the CAT where possible. Proxy measures
and mediators of GP behaviour will be measured through a
paper-based questionnaire (available in Additional file 1 -
IRIS behavioural construct questionnaire).
Data quality assurance
GP questionnaires will be checked for errors and miss-
ing data as they are returned, and GPs will be followed
up to clarify anomalies. Double data entry will be used
to enter GP paper-based questionnaires. InconsistenciesCapability
Opportunity
Figure 2 Hypothesised causal pathway model for the primary outcomwill be investigated by referring back to the paper-based
version. Non-responding GPs will be contacted by phone
to encourage completion of the questionnaire.
Free text entries extracted from the CAT contain a
maximum of 40 characters surrounding the identified
search term, to maintain anonymity of the patients. The
short length of these text extracts is likely to lead to dif-
ficulties in coding variables for some patients. Therefore,
two researchers, who are blind to intervention group,
will independently review the text extracts. To improve
consistency in coding between researchers, a coding dic-
tionary will initially be created from a sample of text ex-
tracts. Disagreements will be resolved via discussion
with a geriatrician who will not be informed of the
group allocation of the patient.
Sample size
The primary outcomes of the IRIS trial include cognitive
assessment using MMSE and depression assessment
using a validated scale in patients with suspected cogni-
tive impairment (cohort 2). The trial has been powered
to detect a difference of 15% in rates of the behaviours
between groups (assuming control group rates of 50%).es.
Table 4 Summary of measurement tools
Outcome or category of outcomes Measurement tool Details
GP behaviour
Cognitive assessment using MMSE CAT electronic search† MMSE results recorded in the patient file or free text indicates an MMSE has been undertaken.
Depression assessment using validated scale CAT electronic search† Geriatric Depression Scale (GDS) results recorded in the patient file or free text indicates GDS, Hamilton Rating
Scale for Depression, Even Briefer Assessment Scale for Depression has been undertaken.
Referral to CDAMS or specialist CAT electronic search† Free text indicates that the patient has been referred to CDAMS, ACAS (Aged Care Assessment Service), or a
geriatrician.
Referral for CT scan CAT electronic search† CT scan has been requested or free text indicates that a CT (head) scan has been requested/undertaken.
Dementia diagnosis CAT electronic search† Coded diagnosis of dementia or free text indicates that the patient has dementia or Alzheimer’s disease.
Cognitive assessment using MMSE
(all patients aged 70+ years)
CAT electronic search† MMSE results recorded in the patient file or free text indicates an MMSE has been undertaken.
Reported suspicion of cognitive impairment
(all patients aged 70+ years)
CAT electronic search† Coded diagnosis of cognitive impairment or free text indicates a suspicion of cognitive impairment (e.g.,
confusion, muddled, cognitive), or; MMSE undertaken in isolation of the 75+ Health Check (an indication of
GP’s suspicion of cognitive impairment), or; MMSE undertaken as part of 75+ Health Check with score
indicating cognitive impairment (i.e., a score between 10 and 24).
Dementia diagnosis (all patients aged 70+ years) CAT electronic search† Coded diagnosis of dementia or free text indicates that the patient has dementia or Alzheimer’s disease.
Proxy measures of GP behaviour
Self-report of adherence to recommended
behaviours
(e.g., Cognitive assessment using MMSE)
Questionnaire*
(1 item per behaviour)
Adapted from Eccles et al. [45]. Example item: ‘Thinking about the last 10 patients you saw who you suspected
had cognitive impairment, how many of them did you assess for cognitive function using the Mini Mental
State Examination (MMSE)?’
Behavioural simulation to adhere to recommended
behaviours (e.g., Cognitive assessment using MMSE)
Questionnaire
(6 clinical vignettes)
Vignettes simulate clinical decision-making about detection, diagnosis and management of dementia. Vignettes
include a range of clinical variables: sex, age (72 – 88 years), cognitive function (including changes to memory,
personality, behaviour, cognition), depression, and other elements. These clinical variables were drawn from
previously published vignettes [46-52] and from the experience of the clinical investigators. The vignettes, and
response options, will be piloted with two to three GPs prior to being administered.
Hypothesised mediators of GP behaviour
Intention to adhere to recommended behaviours
(e.g., Cognitive assessment using MMSE)
Questionnaire*
(3 items per behaviour)
Adapted from Eccles et al. [45], Francis et al. [53],and Foy et al. [54]. Items for Cognitive assessment using MMSE
include ‘I would make it a high priority to use the MMSE to assess the cognitive function of these patients,’ ‘I
plan to use the MMSE to assess the cognitive function of these patients,’ ‘I intend to use the MMSE to assess
the cognitive function of these patients.’ Each item measured on a 7-point Likert scale ranging from strongly
disagree to strongly agree (1 to 7). Scores are then averaged to create a behavioural intention score. Higher
scores reflect greater intention to assess cognitive function using the MMSE.
Behavioural constructs for primary outcomes Questionnaire* Adapted from [34]. There are 49 items in total. Example of the items used to measure various domains (noted
in brackets) for the behaviour depression assessment using a validated scale include: ‘How much do you know
about validated scales for assessing depression in these patients?’ (knowledge), ‘Using a validated scale to
assess these patients for depression is sometimes stressful’ (emotion), ‘Lack of time may prevent me from using
a validated scale to assess these patients for depression’ (environmental context and resources). Each item is
measured on a 7-point Likert scale. All constructs are measured using three items (which are averaged to
create a final score for the construct), except beliefs about consequences, which is measured using four items.
*Questionnaire available in Additional file 1 – IRIS Behavioural construct questionnaire. † Two researchers (with healthcare qualifications), who are blind to intervention group, will independently review the free text
entries to decide if the behaviour has occurred. Disagreements will be resolved via discussion with a geriatrician who will not be informed of the group allocation of the patient.
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http://www.implementationscience.com/content/8/1/91Using sample size formula (2) of Eldridge et al. [55] and
assuming, on average 20 patients per practice are identi-
fied, with a coefficient of variation in practice size of 0.7,
and an intra-cluster correlation of 0.10, 45 practices per
group will be sufficient to detect the 15% increase in
recommended behaviours with 90% power (two-sided
significance level of 5%). Allowing for 25% attrition in
practices, we aim to recruit 60 practices per group. Justi-
fications of the parameters used in the sample size cal-
culation are available in Additional file 2 – IRIS sample
size calculations.
Effectiveness analyses
Analysis subsets
Intention-to-treat (ITT) analyses are generally recom-
mended in randomised trials for the primary reason of
preserving the benefits of randomisation; namely,
maintaining the comparability of the intervention groups
in known and unknown prognostic factors [56]. In
addition, it has been argued that ITT analyses compared
with other analysis strategies (e.g., per-protocol) are
more appropriate for pragmatic trials since they provide
estimates of intervention effect that are more reflective
of what would be observed if the intervention was
implemented in routine clinical practice [57-59].
While requirements of an ideal ITT analysis (including
compliance with the randomised intervention, no miss-
ing responses, and follow-up on all participants [57])
have been established for patient randomised trials, only
recently has there been more detailed discussion of the
definition and application of ITT analyses in C-RTs [60].
In C-RTs with adequate allocation concealment, compar-
ability of intervention groups can be compromised not
only through missing responses and loss to follow-up (as
occurs in patient randomised trials), but also through re-
cruitment of participants occurring post randomisation.
Furthermore, loss to follow-up in cluster trials can occur
at different levels (clusters and patients) because of the
hierarchical structure of the design.
In the IRIS trial, retrospective identification of eligible
participants will be undertaken (post randomisation) by
researchers blind to group allocation, so the potential
for selection bias will be minimised. In addition, bias
arising from missing responses and loss to follow-up at
the patient level will be minimal, since data will be
extracted through the CAT on all eligible patients. How-
ever, practices and GPs may withdraw prior to data be-
ing extracted on their patients, resulting in empty
clusters. A full application of the ITT principle in this
circumstance would require the empty clusters to be
accounted for in the analysis. Accounting for empty
clusters would require strong assumptions to be made
about patient characteristics and outcomes based on GP
or cluster characteristics.We therefore plan to present a modified ITT analysis
as our primary analysis, where we will analyse clusters,
GPs and patients, as they have been randomised, regard-
less of the intervention they have received, but will not
impute missing data. As part of the secondary analyses,
we will attempt to examine the potential impact of
empty clusters on the intervention effects for the pri-
mary outcomes. Reasons for practice and GP withdrawal
will be collected, and even in the circumstance of with-
drawal, we will seek permission to run the CAT to ex-
tract data on patients.
Descriptive analyses at baseline
Descriptive statistics of baseline demographic and poten-
tial confounding variables at the patient, GP, and prac-
tice level will be presented (Table 5). These statistics will
allow assessment of the comparability of intervention
groups at baseline, and provide descriptive information
about the study sample.
Primary analyses
Marginal models using generalised estimating equations
(GEEs) will be fitted for binary outcomes (using a logit
link function) to estimate the effectiveness of the inter-
vention. These models appropriately account for the cor-
relation of responses within practice. We will assume an
exchangeable correlation structure (where responses
from the same practice are assumed to be equally corre-
lated [35,61]) and use robust variance estimation (which
yield valid standard errors of the intervention effect even
if the within-cluster correlation structure has been
misspecified [62,63]). Generalised estimating equations
do not constrain ICCs to be positive; however, in the
context of this trial, the likely explanation for a negative
ICC is sampling variability, and not a true underlying
negative ICC [35,64]. Therefore, in the event that the
ICC from a particular analysis is negative, we will esti-
mate the intervention effect using ordinary logistic re-
gression, which will yield conservative estimates of
standard errors.
The measure of intervention effect arising from the
above models is an odds ratio. To aid interpretation, we
plan to also present risk differences [65]. Risk differences
will be calculated from marginal probabilities estimated
from the fitted models [66]. Confidence intervals for the
risk differences will be calculated using bootstrap
methods, appropriately allowing for the clustered struc-
ture of the data.
Linear mixed models (LMM) will be fitted for continu-
ous outcomes to estimate the effectiveness of the inter-
vention, allowing for clustering with a random practice
effect [67]. Continuous outcomes will only be measured
at the level of the GP (self-report measures, intention,
and behavioural constructs) and there are likely to be
Table 5 Baseline characteristics at patient, GP, and practice level (presented by intervention group)
Patient level GP level Practice level
Cohort 1* Age (years) (mean, SD) No. GPs per practice (mean, SD)
Age (years) (mean, SD) Sex (no., % female) Rural practices (no., %)
Sex (no., % female) No. of years since graduated from medical school (mean, SD) Estimated total number of patients on the practice’s books (mean, SD)
Suspected cognitive impairment (no., %) Country of medical training (Australia or overseas) (no., % Australia) Practice nurse available (no., %)
Involved in undertaking health assessments for people aged ≥75 years (no., %)Cognitive assessment using MMSE (no., %) Yrs. practised in Aust. if overseas medical training (mean, SD)
Undertakes full assessment or part (in combination with GP) (no., %full)
Cohort 2* GP registrar (no., %) Involved in other aged care activities (no., %)
Age (years) (mean, SD) Fellow of RACGP (no., %) Other health practitioners work in the practice (specialist, allied health) (no., %)
Sex (no., % female) Member of GP Division in their region (no., %) Practice formally involved in training GP registrars (no., %)
Cognitive assessment using MMSE (no., %) Hours spent per week in clinical practice (mean, SD) Practice services residential care facilities (no., %)
Depression assessment using validated scale
(no., %)
No. patients seen per week (mean, SD) Method of billing (bulk bill or co-payment) (no., %bulk bill)
Percentage of patients over 70 (mean, SD) Age of practice (years) (mean, SD)
Referral to CDAMS or specialist (no., %) Special interest in dementia (no., %) Ownership (corporate or privately owned) (no., %corporate)
Referral for CT scan (no., %) Special interest in aged care (no., %)
Self-report of adherence to recommended behaviours
(mean, SD)
Intention to adhere to recommended behaviours (mean, SD)
Behavioural constructs for primary outcomes (mean, SD)
*Cohort 1: Active patients aged 70 years and older at baseline. Cohort 2: Active patients aged 70 years and older in whom the GP suspects cognitive impairment at baseline.
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http://www.implementationscience.com/content/8/1/91few practices with multiple GPs. In circumstances where
there are a small proportion of clusters with multiple
observations, LMM have been shown to perform slightly
better than GEEs [68]. For skewed continuous outcomes,
model-based standard errors will be compared with
those obtained from bootstrapping.
Our primary analyses of outcomes will include adjust-
ment for the stratification variables (e.g., geographical lo-
cation of the practice, number of GPs per practice) and
pre-specified potential confounding variables (Figure 3).
The potential confounders have been selected through
discussion with the investigators and examination of the
confounders adjusted for in other similar implementa-
tion trials (e.g., [16,30]). All pre-specified confounders
will be included in the models even when no baseline
imbalance exists, since confounder selection strategies
based on observed data (e.g., selecting confounders using
preliminary statistical tests) result in models with poor
statistical properties (e.g., incorrect type I error rates)
[69-72]. If there are outcomes with limited data or
events, we will only adjust for the stratification variables
and, where appropriate, the baseline of the outcome
variable (e.g., self-report measures, intention, and behav-
ioural constructs). For each outcome, the estimate of
intervention effect and its 95% CI will be provided. For
primary outcomes, we plan to provide estimates of ICCs
and their 95% CI.
Regression diagnostics will be used to assess the influ-
ence of outliers on estimates of intervention effect andOutcomes/confounders A
ge
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tia
Level confounder measured at Patient level
GP behaviour
Cognitive assessment using MMSE
Depression assessment using validated scale
Referral to CDAMS or specialist
Referral for CT scan
Dementia diagnosis
Cognitive assessment using MMSE
(all patients aged 70+ years)
Reported suspicion of cognitive impairment
(all patients aged 70+ years)
Dementia diagnosis (all patients aged 70+ years)
Proxy measures of GP behaviour
Self-report of adherence to recommended behaviour
Behavioural simulation to adhere to recommended behaviour
Hypothesised mediators of GP behaviour
Intention to adhere to recommended behaviour
Behavioural construct for primary outcomes
* Stratification variable.
Figure 3 Potential confounding variables adjusted for in the primaryfor analysing residuals. No adjustment will be made for
multiple testing. All tests will be two-sided and carried
out at the 5% level of significance.
Secondary analyses
GEEs fitted to binary outcomes yield unbiased estimates
of intervention effect only when data are missing com-
pletely at random [73]. As noted previously (in the ‘Ana-
lysis subsets’ section), empty clusters arising from
practices or GPs withdrawing post randomisation but
prior to extraction of patient data may occur, and this
may introduce bias. We will attempt to examine the po-
tential impact of empty clusters on the intervention ef-
fects for the primary outcomes using weights to allow
for patterns of ‘missingness’ [74]. Weights will be cre-
ated based on proxy measures of clinical behaviour for
the key recommendations (e.g., self-report adherence to
cognitive assessment using MMSE, intention to adhere
to cognitive assessment using MMSE).
Two inclusion criteria used to define cohort 2 (pa-
tients with suspected cognitive impairment) are based
on use of the MMSE in the baseline period. If GPs sus-
pect cognitive impairment, patients should receive fur-
ther assessments using the MMSE, regardless of whether
they have been previously assessed. The rate of MMSE
assessment is likely to be higher in patients who have re-
ceived a previous MMSE, since their GP is already more
likely to adhere to this recommendation. Consequently,
an MMSE assessment in the baseline period may modifyN
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http://www.implementationscience.com/content/8/1/91the intervention effect for the primary outcome of cog-
nitive assessment using MMSE. We will examine this by
fitting a model that includes an interaction term be-
tween the intervention group and an administration of
the MMSE in the baseline period.
For the primary outcomes, we plan to undertake a
per-protocol analysis to estimate the effect of the inter-
vention for the subgroup of GPs who comply with the
intervention. Compliance to the intervention is defined
as attendance at the workshop.
We plan to undertake explanatory analyses for the pri-
mary outcomes to examine if intervention effects are
explained by our hypothesized mediators of practitioner
behaviour (Figure 2) [75-78]. These explanatory analyses
will form a separate publication.
In the IRIS trial, some behaviours will be measured
both objectively (through medical records) and subject-
ively (self-report and behavioural simulation). When ob-
jective measures are available, we will examine the
predictive validity of the subjective measures; this will
aid in interpretation of the subjective measures and con-
tribute evidence of their measurement properties.
Economic evaluation
Several recent studies have estimated the costs and ben-
efits of early diagnosis and timely intervention for de-
mentia. Banerjee and Wittenberg (2009) conducted a
modelled cost-utility analysis comparing the use of
multidisciplinary, interagency teams for the early diagno-
sis and treatment of dementia (Croydon Memory Service
Model) against usual care in England. Results from this
analysis suggested that ‘…a gain of between 0.01 and
0.02 QALYs per person year …plus a 10% diversion of
people with dementia from residential care …would be
sufficient to render the service cost-effective (in terms of
positive net present value)’ [79]. While Banerjee and
Wittenberg suggested that such improvements ‘seem very
likely to be achievable,’ the available evidence for the
effectiveness of the Croydon Memory Service Model is
limited and subject to a high risk of bias [80]. Wolfs et al.
conducted cost utility and cost effectiveness analyses
alongside the Maastricht Evaluation of a Diagnostic
Intervention for Cognitively Impaired Elderly (MEDICIE)
C-RT to compare diagnosis and intervention through the
Diagnostic Observation Centre for Psycho-Geriatric Pa-
tients (DOC-PG) against usual care in the Netherlands.
Results from the cost-utility analysis suggested that the
DOC-PG yields an average gain of 0.05 of a QALY over
usual care at an average incremental cost of just €65
(€1267 per QALY gained). While the probability that the
DOC-PG was cost-effective exceeded 50% at a funding
threshold of €20,000 per QALY, there remained a 20%
probability that usual care is more cost-effective than the
DOC-PG even at a threshold of €80,000 [81].The interventions evaluated in each of these previous
studies entail care outside of general practice by, for ex-
ample, commissioning ‘a new service to work in a com-
plementary way with existing primary and secondary
care services’ [81]. Treatment effects are achieved via a
change in practitioner rather than a change in clinical
practice (behaviour change). Such an approach may not
be suited to all settings. The economic evaluation to be
conducted alongside the IRIS trial will be the first to es-
timate the costs and benefits associated with changing
clinical practice within the existing and dominant model
of primary care in Australia to improve the adherence of
general practitioners to recommended behaviours for
the detection and diagnosis of dementia.
Specifically, cost effectiveness analyses will be conducted
alongside the IRIS C-RT to quantify the additional costs
(savings) and improvements in adherence to the CPG
arising from delivery of the IRIS implementation inter-
vention, compared with passive dissemination of the
CPG. Evaluation of costs and health gains arising from
delivery of the intervention (ex post of development of
the implementation intervention) will be informative to
policy-makers and hospital administrators considering
a wider roll-out of the IRIS implementation interven-
tion [82]. Secondary aims will be to determine whether
the incremental treatment costs of the IRIS interven-
tion are offset by reductions in health service expenditure
within the trial period (i.e., whether implementation is
cost-saving as compared with existing practice), and to
determine whether the IRIS intervention dominates
existing practice (i.e., less costly but no less effective).
The time horizons for inclusion of relevant costs and
consequences for the trial-based evaluation described
here will be limited to the period of follow-up of partic-
ipants in cohorts 1 and 2 (nine months post-delivery of
the intervention).
The economic evaluation alongside the IRIS C-RT will
take a health sector perspective in identifying, measuring
and valuing costs and consequences within the time
horizon. The time horizon for the IRIS trial necessarily
excludes costs and consequences beyond the short-run
effects observable in the trial excepting insofar as they
are reflected in adherence to the key-recommendations
of the CPG. In addition, we exclude some dimensions of
adherence not captured by the primary effectiveness out-
comes. Research and evaluation costs will be excluded
except where they might plausibly contribute to a clinic-
ally significant treatment effect. Costs common and in-
variant to both intervention and control groups (e.g.,
costs associated with development and standard dissem-
ination of the guideline) will not be explicitly calculated
for the incremental analysis described here. Finally, some
cost categories unlikely to produce clinically and eco-
nomically significant variation in incremental cost will
McKenzie et al. Implementation Science 2013, 8:91 Page 16 of 18
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attending treatment) to simplify our analysis [83].
Additional methods for the economic evaluation
alongside the IRIS trial including methods for the identi-
fication, measurement and valuation of outcomes and
resource use are described in Additional file 3 – IRIS
additional methods for the economic evaluation. Results
from the economic evaluation alongside the IRIS trial
will be expressed as: additional costs (savings) per add-
itional patient assessed using MMSE and additional
costs (savings) per additional patient receiving depres-
sion assessment using validated scale.
Publication policy
The results from the trial will be published regardless of
the outcome. Reporting of this trial will adhere to the
relevant, and most up-to-date, CONSORT (Consolidated
Standards of Reporting Trials) statement [84] and its
relevant extensions [65,85,86].
Ethical review
Ethical approval for this trial was obtained from the
Monash University Human Research Ethics Committee
(CF11/0727 – 2011000192, CF09/3631 - 2009001968).
The investigators will ensure that the trial is conducted in
compliance with this protocol and the Australian National
Statement on Ethical Conduct in Human Research [87].
Additional files
Additional file 1: IRIS behavioural construct questionnaire. This file
includes the behavioural construct questionnaire.
Additional file 2: IRIS sample size calculations. This file provides
details of the sample size calculations used in IRIS.
Additional file 3: IRIS additional methods for the economic
evaluation. This file provides additional details of the methods used for
the economic evaluation alongside the IRIS trial.
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